The 2025 ASCO Annual Meeting brought groundbreaking advances and transformative developments to the oncology sphere. The event has long been a cornerstone for introducing innovative treatment paradigms and groundbreaking research in cancer therapy. This year, the conference sustained this trend by
What if the secret to faster and more effective cancer treatments isn't found in conventional laboratories but within the algorithms of artificial intelligence instead? Drug development has long been a drawn-out process, often taking over a decade to bring a new medication from concept to market.
With over ten million people worldwide battling Parkinson's disease, the quest for a treatment that not only controls symptoms but also halts the progression of this neurological disorder is of immense importance. Roche's recent advancement of prasinezumab, developed with Prothena, into Phase 3
In the swiftly changing world of biopharmaceuticals, the role of artificial intelligence (AI) is rapidly expanding, driving interest and speculation about its potential transformative effects on the industry. This landscape isn't just challenged by scientific demands but also by economic pressures,
In a major breakthrough in the field of drug development, revolutionary nanotechnology known as Facilitated Self-Assembling Technology (FAST) has been unveiled, promising to drastically transform drug solubility. Spearheaded by Stephen Hsu, PhD, a professor at the Dental College of Georgia, FAST
Ivan Kairatov is an esteemed biopharma expert with extensive knowledge in technological innovation within the industry, particularly in research and development. Today, we'll delve into the recent FDA approval of Regeneron's Lynozyfic for multiple myeloma and its implications for patients and
